tradingkey.logo
tradingkey.logo
Suchen

Evotec SE

EVO
Zur Watchlist hinzufügen
2.900USD
+0.050+1.75%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
1.03BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Evotec SE Unternehmen

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Evotec SE Informationen

BörsenkürzelEVO
Name des UnternehmensEvotec SE
IPO-datumOct 11, 1999
CEOWojczewski (Christian)
Anzahl der mitarbeiter4827
WertpapierartDepository Receipt
GeschäftsjahresendeOct 11
AddresseEssener Bogen 7
StadtHAMBURG
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl22419
Telefon4940560810
Websitehttps://www.evotec.com/
BörsenkürzelEVO
IPO-datumOct 11, 1999
CEOWojczewski (Christian)

Führungskräfte von Evotec SE

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Roland Sackers
Mr. Roland Sackers
Independent Vice Chairman of the Supervisory Board
Independent Vice Chairman of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Laetitia Rouxel
Ms. Laetitia Rouxel
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
--
--
Mrs. Aurelie Dalbiez
Mrs. Aurelie Dalbiez
Chief People Officer, Member of the Management Board
Chief People Officer, Member of the Management Board
--
--
Dr. Christian Wojczewski
Dr. Christian Wojczewski
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Duncan Mchale
Dr. Duncan Mchale
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Cord Dohrmann, Ph.D.
Dr. Cord Dohrmann, Ph.D.
Chief Scientific Officer, Member of the Management Board
Chief Scientific Officer, Member of the Management Board
--
--
Prof. Dr. Iris Loewfriedrich
Prof. Dr. Iris Loewfriedrich
Independent Chairwoman of the Supervisory Board
Independent Chairwoman of the Supervisory Board
--
--
Mr. Roland Sackers
Mr. Roland Sackers
Independent Vice Chairman of the Supervisory Board
Independent Vice Chairman of the Supervisory Board
--
--
Dr. Constanze Ulmer-Eilfort
Dr. Constanze Ulmer-Eilfort
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Volker Braun
Mr. Volker Braun
Senior Vice President, Head of Global Investor Relations and ESG
Senior Vice President, Head of Global Investor Relations and ESG
--
--
Ms. Camilla Macapili Languille
Ms. Camilla Macapili Languille
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Evotec SE?

Die fünf größten Anteilseigner von Evotec SE sind: Dr. Cord Dohrmann, Ph.D.

Wie viele Institutionen halten Anteile an Evotec SE (EVO)?

Mit Stand vom 2026Q1 halten 81 Institutionen Anteile an Evotec SE, mit einem Gesamtmarktwert von etwa 9.58M, was 2.69% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -584606.00 gestiegen.